natgillin/translations-raw huggingface dataset:
- Fesoterodin, solifenacin(til behandling af sygdomme i urinvejene). 
Fesoterodine, solifenacin(to treat urologic disorders).
Hvis du har taget for meget Darunavir Krka 
If you forget to take Darunavir Krka
Pravastatin 40 mg som enkeltdosis pravastatin AUC ↑ 81% 
Pravastatin 40 mg single dose pravastatin AUC ↑ 81% pravastatin Cmin ND pravastatin Cmax ↑ 63%
Samtidig administration af boostet darunavir og dabigatran eller ticagrelor er kontraindiceret (se pkt. 
Concomitant administration of boosted darunavir with dabigatran or ticagrelor is contraindicated (see section 4.3).
Darunavir bindes hovedsageligt til surt α1-glykoprotein. 
Darunavir binds predominantly to α1-acid glycoprotein.
Farmakokinetiske resultater for total-darunavir efter administration af 800/150 mg darunavir/cobicistat en gang dagligt som del af et antiretroviralt regime i andet trimester af graviditeten, tredje trimester af graviditeten og post partum Farmakokinetik for total-darunavir (Gennemsnit ± SD) 
Pharmacokinetic results of total darunavir after administration of darunavir/cobicistat 800/150 mg once daily as part of an antiretroviral regimen, during the second trimester of pregnancy, the third trimester of pregnancy, and postpartum Pharmacokinetics of total darunavir (mean ± SD)
For yderligere oplysninger om cobicistat, se produktresuméet for cobicistat. 
For further information on cobicistat, consult the cobicistat Summary of Product Characteristics.
Der er observeret øget systemisk eksponering af darunavir ved samtidig brug af rifabutin (150 mg hver anden dag) og darunavir administreret sammen med 100 mg ritonavir. 
An increase of systemic exposure to darunavir was observed when darunavir co-administered with 100 mg ritonavir was co-administered with rifabutin (150 mg once every other day).
150 mg to gange daglig darunavir AUC ↔ darunavir Cmin ↔ darunavir Cmax ↔ 
150 mg twice daily darunavir AUC ↔ darunavir Cmin ↔ darunavir Cmax ↔
Darunavir administreret sammen med lavdosis ritonavir må ikke anvendes samtidig med produkter, der indeholder perikon (Hypericum perforatum) (se pkt. 
Darunavir co-administered with low dose ritonavir must not be used concomitantly with products containing St John's wort (Hypericum perforatum) (see section 4.3).
Boostet darunavir med triazolam eller oral midazolam er kontraindiceret (se pkt. 
Boosted darunavir with triazolam or oral midazolam is contraindicated (see section 4.3)
Blod og lymfesystemet ikke almindelig trombocytopeni, neutropeni, anæmi, leukopeni sjælden forøget eosinofiltal 
Blood and lymphatic system disorders uncommon thrombocytopenia, neutropenia, anaemia, leukopenia rare increased eosinophil count
Virkning af darunavir 800 mg en gang dagligt co-administreret med 100 mg ritonavir en gang dagligt hos ART-erfarne patienter 
Efficacy of darunavir 800 mg once daily co-administered with 100 mg ritonavir once daily in ARTexperienced patients
400 mg filmovertrukne tabletter: 
400 mg film-coated tablets:
Darunavir Krka 600 mg filmovertrukne tabletter må ikke tygges eller knuses. 
Darunavir KrKa 600 mg film coated tablets must not be chewed or crushed.
Samtidig anvendelse af salmeterol og boostet darunavir anbefales ikke. 
Concomitant use of salmeterol and boosted darunavir is not recommended.
induktorer er kontraindiceret, eftersom disse kan reducere eksponeringen forcobicistat og darunavir med efterfølgende tab af terapeutisk effekt. 
Concomitant use with strong CYP3A inducers is contraindicated, since these may reduce the exposure to cobicistat and darunavir leading to loss of therapeutic effect.
Der skal udvises forsigtighed, og om muligt anbefales monitorering af terapeutisk koncentration for disse antiarytmika ved coadministration med darunavir og lavdosis ritonavir. 
Caution is warranted and therapeutic concentration monitoring, if available, is recommended for these antiarrhythmics when coadministered with darunavir with low dose ritonavir.
800 mg filmovertrukne tabletter: 
800 mg film-coated tablets:
Behandling med darunavir/cobicistat 800/150 mg under graviditet fører til lav eksponering for darunavir (se pkt. 
Treatment with darunavir/cobicistat 800/150 mg during pregnancy results in low darunavir exposure (see sections 4.4 and 5.2).
Perikon forventes at nedsætte plasmakoncentrationen af darunavir og ritonavir. 
St John's wort is expected to decrease the plasma concentrations of darunavir and ritonavir.
Darunavir co-administreret med lavdosis ritonavir, bør kun anvendes under graviditet, hvis den mulige fordel opvejer den mulige risiko. 
Darunavir co-administered with low dose ritonavir should be used during pregnancy only if the potential benefit justifies the potential risk.
Co-administration med darunavir co-administreret med cobicistat kan ikke anbefales (se pkt. 
Co-administration with darunavir coadministered with cobicistat is not recommended (see section 4.4).
Der er ikke anbefalet dosisjustering af darunavir/ritonavir. 
No dose adjustment for darunavir /ritonavir is recommended.
Det anbefales ikke at coadministrere darunavir med lavdosis ritonavir og boceprevir. 
It is not recommended to coadminister darunavir with low dose ritonavir and boceprevir.
Darunavir boostet med cobicistat er mere følsomt over for CYP3A-induktion: samtidig brug af darunavir/cobicistat og potente CYP3A-induktorer er derfor kontraindiceret (se pkt. 
Darunavir boosted with cobicistat is more sensitive for CYP3A induction: concomitant use of darunavir/cobicistat and strong CYP3A inducers is therefore contraindicated (see section 4.3),and concomitant use with weak to moderate CYP3A inducers is not recommended (see section 4.5).
Co-administration af domperidon og boostet darunavir er kontraindiceret. 
Co-administration of domperidone with boosted darunavir is contraindicated.
Interaktionsprofilen for darunavir er afhængig af, om ritonavir eller cobicistat benyttes som farmakokinetisk forstærker. 
The interaction profile of darunavir depends on whether ritonavir or cobicistat is used as pharmacokinetic enhancer.
Interaktionsprofilen for darunavir kan være forskellig afhængigt af, om ritonavir eller cobicistat benyttes som farmakokinetisk forstærker. 
The interaction profile of darunavir may differ depending on whether ritonavir or cobicistat is used as pharmacoenhancer.
Samtidig anvendelse af cochicin og boostet darunavir kan øge eksponeringen for colchicin. 
Concomitant use of colchicine and boosted darunavir may increase the exposure to colchicine.
Brug af boostet darunavir sammen med disse antikoagulantia frarådes. 
The use of boosted darunavir and these anticoagulants is not recommended.
(til behandling af depression og angst) - Maraviroc (til hiv-infektion) - Methadon (til behandling af opioidafhængighed) - Carbamazepin, clonazepam (til forebyggelse af krampeanfald eller til behandling af visse typer nervesmerter) - Colchicin (til behandling af urinsur gigt eller familiær middelhavsfeber) - Bosentan (til behandling af for højt blodtryk i lungekredsløbet) - Buspiron, clorazepat, diazepam, estazolam, flurazepam, midazolam, når det tages som injektion, zoldipem (beroligende midler) - Perphenazin, risperidon, thioridazin (til behandling af psykiske lidelser) - Metformin (til behandling af type 2-diabetes). 
Carbamazepine, clonazepam(to prevent seizures or to treat certain types of nerve pain) Colchicine (to treat gout or familial Mediterranean fever) Bosentan (to treat high blood pressure in the pulmonary circulation) Buspirone, clorazepate, diazepam, estazolam, flurazepam, midazolam when used as injection, zoldipem (sedative agents)
Samtidig anvendelse af salmeterol og boostet darunavir kan øge plasmakoncentrationen af salmeterol. 
Concomitant use of salmeterol and boosted darunavir may increase plasma concentrations of salmeterol.
Coadministration af darunavir og ritonavir med lægemidler, som primært metaboliseres af CYP2D6 (såsom flecainid, propafenon, metoprolol), kan resultere i en øget plasmakoncentration af disse lægemidler, hvilket kan øge eller forlænge deres terapeutiske effekt og bivirkninger. 
Co-administration of darunavir and ritonavir with medicinal products which are primarily metabolised by CYP2D6 (such as flecainide, propafenone, metoprolol) may result in increased plasma concentrations of these medicinal products, which could increase or prolong their therapeutic effect and adverse reactions.
≥15 kg-<30 kg 600 mg darunavir/100 mg ritonavir en gang dagligt 
≥ 15 kg-< 30 kg 600 mg darunavir/100 mg ritonavir once daily
Hud og subkutane væv almindelig udslæt (herunder makuløst, makulopapuløst, papuløst, erytematøst og kløende udslæt), pruritus ikke almindelig angioødem, generaliseret udslæt, allergisk dermatitis, urticaria, eksem, erytem, hyperhidrose, nattesved, alopeci, akne, tør hud, neglepigmentering sjælden 
Skin and subcutaneous tissue disorders common rash (including macular, maculopapular, papular, erythematous and pruritic rash), pruritus uncommon angioedema, generalised rash, allergic dermatitis, urticaria, eczema, erythema, hyperhidrosis, night sweats, alopecia, acne, dry skin, nail pigmentation rare
600 mg en gang daglig efavirenz AUC ↑ 21% efavirenz Cmin ↑ 17% efavirenz Cmax ↑ 15% darunavir AUC ↓ 13% darunavir Cmin ↓ 31% darunavir Cmax ↓ 15% (↑ efavirenz fra CYP3Ahæmning) (↓ darunavir fra CYP3Ainduktion) 
600 mg once daily efavirenz AUC ↑ 21% efavirenz Cmin ↑ 17% efavirenz Cmax ↑ 15% darunavir AUC ↓ 13% darunavir Cmin ↓ 31% darunavir Cmax ↓ 15% (↑ efavirenz from CYP3A inhibition) (↓ darunavir from CYP3A induction)
Hver filmovertrukken tablet indeholder 400 mg eller 800 mg darunavir. 
Each film-coated tablet contains 400 mg or 800 mg darunavir.
Metabolisme og ernæring almindelig diabetes mellitus, hypertriglyceridæmi, hyperkolesterolæmi, hyperlipidæmi ikke almindelig artritis urica, anoreksi, nedsat appetit, vægttab, vægtstigning, hyperglykæmi, insulinresistens, nedsat HDL, øget appetit, polydipsi, øget lactatdehydrogenase i blodet 
Metabolism and nutrition disorders common diabetes mellitus, hypertriglyceridaemia, hypercholesterolaemia, hyperlipidaemia uncommon gout, anorexia, decreased appetite, decreased weight, increased weight, hyperglycaemia, insulin resistance, decreased high density lipoprotein, increased appetite, polydipsia, increased blood lactate dehydrogenase
Patientandelen (%)med respons(hiv-1-RNA < 50 kopier/ml ved uge 24) over for darunavir co-administreret med ritonavir (600/100 mg to gange dagligt) efter genotype ved baselinea og darunavir FC ved baseline og efter brug af enfuvirtid (ENF): ”As treated-analyse” af POWER- og DUET-studierne. 
Proportion (%) of patients with response (HIV-1 RNA < 50 copies/ml at week 24) to darunavir coadministered with ritonavir (600/100 mg twice daily) by baseline genotype a, and baseline darunavir
Der skal udvises forsigtighed, når clarithromycin kombineres med darunavir administreret sammen med lavdosis ritonavir. 
Caution should be exercised when clarithromycin is combined with darunavir co-administered with low dose ritonavir.
Baseret på teoretiske overvejelser forventes coadministreret boostet darunavir at øge eksponeringen for lomitapid. 
Based on theoretical considerations boosted darunavir is expected to increase the exposure of lomitapide when coadministered.
Dosis til voksne, som tidligere har fået hiv-medicin (din læge vil afgøre dette) 
in certain patients who have used antiretroviral medicines before (your doctor will determine this).
Den anbefalede dosis er 800 mg en gang dagligt sammen med ritonavir 100 mg en gang dagligt i forbindelse med et måltid. 
The recommended dose regimen is 800 mg once daily with ritonavir 100 mg once daily taken with food.
Et dosisregime med darunavir taget med ritonavir en gang dagligt i forbindelse med et måltid kan anvendes til patienter, der tidligere har været eksponeret for antiretrovirale lægemidler, men uden mutationer associeret med darunavirresistens (DRV-RAMs)*, og som har plasma-hiv-1-RNA < 100.000 kopier/ml og CD4+-celletal  100 x 10 celler /l. 
A once daily dose regimen of darunavir taken with ritonavir taken with food may be used in patients with prior exposure to antiretroviral medicinal products but without darunavir resistance associated mutations (DRV-RAMs)* and who have plasma HIV-1 RNA < 100,000 copies/ml and CD4+ cell count ≥ 100 cells x 10
Darunavir Krka kan muligvis øge risikoen for forhøjet kaliumindhold i blodet pga. drospirenon. 
Darunavir Krka might increase the risk for elevated potassium levels by drospirenone.
I andet trimester af graviditeten var værdierne for Cmax, AUC24t og Cmin for cobicistat hhv. 50 %, 63 % og 83 % lavere i forhold til post partum. 
During the second trimester of pregnancy, cobicistat Cmax, AUC24h, and Cmin were 50%, 63%, and 83% lower, respectively, as compared with postpartum.
Lopinavir/ritonavir 533/133,3 mg to gange daglig lopinavir AUC ↑ 9% lopinavir Cmin ↑ 23% lopinavir Cmax ↓ 2% darunavir AUC ↓ 38%‡ darunavir Cmin ↓ 51%‡ darunavir Cmax ↓ 21%‡ lopinavir AUC ↔ lopinavir Cmin ↑ 13% lopinavir Cmax ↑ 11% darunavir AUC ↓ 41% darunavir Cmin ↓ 55% darunavir Cmax ↓ 21% baseret på ikkedosisnormaliserede værdier 
Lopinavir/ritonavir 533/133.3 mg twice daily lopinavir AUC ↑ 9% lopinavir Cmin ↑ 23% lopinavir Cmax ↓ 2% darunavir AUC ↓ 38% darunavir Cmin ↓ 51% darunavir Cmax ↓ 21% lopinavir AUC ↔ lopinavir Cmin ↑ 13% lopinavir Cmax ↑ 11% darunavir AUC ↓ 41% darunavir Cmin ↓ 55% darunavir Cmax ↓ 21% based upon non dose normalised values
Der er kun begrænset erfaring med akut overdosering af darunavir, co-administreret med cobicistat eller lavdosis ritonavir, hos mennesker. 
Human experience of acute overdose with darunavir co-administered with cobicistat or low dose ritonavir is limited.
Post partum (6-12 uger) (n=12) 
Postpartum (6-12 weeks) (n=12)
Samtidig administration af 
Method of administration
Virkning af darunavir 800 mg en gang dagligt co-administreret med 100 mg ritonavir en gang dagligt hos ART-naive patienter 
Efficacy of darunavir 800 mg once daily co-administered with 100 mg ritonavir once daily in ARTnaïve patients
Darunavir Krka, anvendes til behandling af hiv-infektion (hiv: humant immundefektvirus). 
Darunavir Krka is an antiretroviral medicine used in the treatment of Human Immunodeficiency Virus (HIV) infection.
Co-administration af darunavir co-administreret med cobicistat og bosentan frarådes. 
Co administration of darunavir coadministered with cobicistat and bosentan is not recommended.
I tredje trimester af graviditeten var værdierne for Cmax, AUC24t og Cmin for cobicistat hhv. 27 %, 49 % og 83 % lavere i forhold til post partum. 
During the third trimester of pregnancy, cobicistat Cmax, AUC24h, and Cmin, were 27%, 49%, and 83% lower, respectively, as compared with postpartum.
Kombinationen af rifapentin og darunavir med samtidig lavdosis ritonavir frarådes. 
The combination of rifapentine and darunavir with concomitant low dose ritonavir is not recommended.
Knogler, led, muskler og bindevæv ikke almindelig myalgi, osteonekrose, muskelspasmer, muskelsvaghed, artralgi, smerter i ekstremiteter, osteoporose, forhøjet kreatinphospho-kinase i blodet sjælden stivhed i skeletmuskulaturen, artritis, ledstivhed 
Musculoskeletal and connective tissue disorders uncommon myalgia, osteonecrosis, muscle spasms, muscular weakness, arthralgia, pain in extremity, osteoporosis, increased blood creatine phosphokinase rare musculoskeletal stiffness, arthritis, joint stiffness
Adskillige af interaktionsstudierne (markeret med # i tabellen nedenfor) er gennemført med doser af darunavir, der er lavere end de anbefalede doser, eller med et andet doseringsregime (se pkt. 
# in the table below) have been performed at lower than recommended doses of darunavir or with a different dosing regimen (see section 4.2 Posology).
Anvisninger for voksne - Tag hver dag 2 tabletter på 400 mg på samme tidspunkt, eller 1 tablet på 800 
Take two 400 milligram tablets at the same time or one 800 miligram tablet, once a day, every day.
450 mg Darunavir Krka + 60 mg ritonavir to gange dagligt mere end 40 kg* 
450 milligram darunavir + 60 milligram ritonavir twice a day more than 40 kilograms*
600 mg darunavir/100 mg ritonavir to gange dagligt ritonavir oral opløsning: 80 mg/ml 
600 mg darunavir /100 mg ritonavir twice daily with ritonavir oral solution: 80 mg/ml
Lopinavir/ritonavir 400/100 mg to gange daglig + OBR N=297 
Lopinavir/ritonavir 400/100 mg twice daily + OBR N=297
Dosering to gange dagligt 
Twice daily dosing Weight
Samtidig brug af darunavir med lavdosis ritonavir og elbasvir/grazoprevir er kontraindiceret (se pkt. 
Concomitant use of darunavir with low dose ritonavir and elbasvir/grazoprevir is contraindicated (see section 4.3).
(CYP3A, CYP2D6 og/eller Pgp-hæmning) 
(CYP3A, CYP2D6 and/or P-gp inhibition)
Det anbefales at bruge andre eller supplerende svangerskabsforebyggende metoder, når østrogenbaserede kontraceptiva gives sammen med boostet darunavir. 
Alternative or additional contraceptive measures are recommended when oestrogen-based contraceptives are co-administered
Produktresuméet for ritonavir skal derfor læses, inden behandling med darunavir påbegyndes. 
The Summary of Product Characteristics of ritonavir must, therefore, be consulted prior to initiation of therapy with darunavir.
21 ART-erfarne hiv-1-smittede pædiatriske patienter i alderen 3 til <6 år med en legemsvægt på 10 kg til <20 kg (16 deltagere fra 15 kg til <20 kg) som fik darunavir oral suspension med lavdosis ritonavir to gange daglig i kombination med andre antiretrovirale lægemidler. 
21 ART-experienced HIV-1 infected paediatric patients aged from 3 to < 6 years and weighing 10 kg to < 20 kg (16 participants from 15 kg to < 20 kg) who received darunavir oral suspension with low dose ritonavir twice daily in combination with other antiretroviral agents.
Darunavir Krka kan nedsætte virkningen af disse. 
Darunavir Krka might reduce its effectiveness.
Samtidig anvendelse af bosentan og boostet darunavir kan øge plasmakoncentrationen af bosentan. 
Concomitant use of bosentan and boosted darunavir may increase plasma concentrations of bosentan.
Plasmakoncentrationen af lovastatin og simvastatin forventes at stige markant, når de gives sammen med boostet darunavir. 
Lovastatin and simvastatin are expected to have markedly increased plasma concentrations when coadministered with boosted darunavir.
Antal deltagere med virologisk svigt og parrede fænotyper ved baseline/endepunkt, der udviste tab af følsomhed over for PI'er ved endepunktet sammenlignet med baseline, n/N 
Number of subjects with virologic failure and paired baseline/endpoint phenotypes, showing loss of susceptibility to PIs at endpoint compared to baseline, n/N PI darunavir amprenavir atazanavir indinavir lopinavir saquinavir tipranavir
Almene symptomer og reaktioner på administrationsstedet almindelig asteni, træthed ikke almindelig pyrexi, brystsmerter, perifert ødem, utilpashed, varmefølelse, irritabilitet, smerte sjælden kulderystelse, unormal følelse, tørhed 
General disorders and administration site conditions common asthenia, fatigue uncommon pyrexia, chest pain, peripheral oedema, malaise, feeling hot, irritability, pain rare chills, abnormal feeling, xerosis
Samtidig administration af darunavir med lavdosis ritonavir og lurasidon, pimozid eller sertindol er kontraindiceret (se pkt. 
Concominant administration of darunavir with low dose ritonavir and lurasidone, pimozide or sertindole is contraindicated (see section 4.3).
Samtidig systemisk brug af clotrimazol og darunavir med samtidigt administreret lavdosis ritonavir kan øge plasmakoncentrationen af darunavir og/eller clotrimazol. 
Concomitant systemic use of clotrimazole and darunavir co-administered with low dose ritonavir may increase plasma concentrations of darunavir and/or clotrimazole.
Mave-tarm-kanalen meget almindelig diarré almindelig opkastning, kvalme, abdominale smerter, forhøjet blodamylase, dyspepsi, abdominal distention, flatulens ikke almindelig pankreatitis, gastritis, gastroøsofageal reflukssygdom, aftøs stomatitis, opkastningsfornemmelser, mundtørhed, mavebesvær, forstoppelse, forhøjet lipase, ræben, oral dysæstesi sjælden stomatitis, hæmatemese, keilit, tørre læber, belægninger på tungen 
Gastrointestinal disorders very common diarrhoea common vomiting, nausea, abdominal pain, increased blood amylase, dyspepsia, abdominal distension, flatulence uncommon pancreatitis, gastritis, gastrooesophageal reflux disease, aphthous stomatitis, retching, dry mouth, abdominal discomfort, constipation, increased lipase, eructation, oral dysaesthesia rare stomatitis, haematemesis, cheilitis, dry lip, coated tongue
Andre kortikosteroider: 
CORTICOSTEROIDS
Boostet darunavir må ikke anvendes samtidig med produkter, der indeholder perikon (Hypericum perforatum) (se pkt. 
Boosted darunavir must not be used concomitantly with products containing St John's wort (Hypericum perforatum) (see section 4.3).
Co-administration af darunavir, lavdosis ritonavir og sildenafil til behandling af pulmonal arteriel hypertension er derfor kontraindiceret (se pkt. 
Therefore, co-administration of darunavir with low dose ritonavir and sildenafil when used for the treatment of pulmonary arterial hypertension is contraindicated (see section 4.3).
Den sædvanlige dosis af Darunavir Krka er 800 mg (2 tabletter a 400 mg Darunavir Krka eller 1 tablet a 800 mg Darunavir Krka) en gang dagligt. 
The usual dose of Darunavir Krka is 800 milligram (2 tablets containing 400 milligram of Darunavir Krka or 1 tablet containing 800 milligram of Darunavir Krka) once daily.
Der er ikke behov for dosisjustering hos patienter med nedsat nyrefunktion (se pkt. 
Renal impairment No dose adjustment is required in patients with renal impairment (see sections 4.4 and 5.2).
ELLER - 600 mg Darunavir Krka (1 tablet a 600 mg Darunavir Krka) sammen med 100 mg ritonavir to gange dagligt. 
600 milligram Darunavir Krka (1 tablet containing 600 milligram of Darunavir Krka) together with 100 milligram ritonavir twice daily.
Samtidig brug af boostet darunavir og elbasvir/grazoprevir er kontraindiceret (se pkt. 
Concomitant use of boosted darunavir and elbasvir/grazoprevir is contraindicated (see section 4.3).
En sikker og effektiv dosis af sildenafil til behandling af pulmonal arteriel hypertension administreret sammen med darunavir og lavdosis ritonavir.er ikke fastlagt. 
A safe and effective dose of sildenafil for the treatment of pulmonary arterial hypertension co-administered with darunavir and low dose ritonavir has not been established.
Samtidig administration af boostet darunavir og lurasidon, pimozid eller sertindol er kontraindiceret (se pkt. 
Concominant administration of boosted darunavir and lurasidone, pimozide or sertindole is contraindicated (see section 4.3).
Klinisk monitoring anbefales ved administration af boostet darunavir og lavdosis ritonavir sammen med disse analgetika. 
Clinical monitoring is recommended when co-administering darunavir with low dose ritonavir with these analgesics.
Darunavir bør ikke anvendes til pædiatriske patienter under 3 år eller med en legemsvægt under 15 kg (se pkt. 
Darunavir should not be used in paediatric patients below 3 years of age or less than 15 kg body weight (see sections 4.4 and 5.3).
Darunavir Krka 800 mg filmovertrukne tabletter (tabletter): 
Darunavir Krka 800 mg film-coated tablets (tablets):
Luftveje, thorax og mediastinum ikke almindelig dyspnø, hoste, næseblødning, halsirritation sjælden næseflåd 
Respiratory, thoracic and mediastinal disorders uncommon dyspnoea, cough, epistaxis, throat irritation rare rhinorrhoea
Darunavir Krka 400 mg og 800 mg tabletter kan anvendes til at sammensætte regimet med 800 mg en gang dagligt. 
Darunavir Krka 400 mg and 800 mg tablets can be used to construct the once daily 800 mg regimen.
Samtidig systemisk brug af clotrimazol og boostet darunavir kan øge plasmakoncentrationen af darunavir og/eller clotrimazol. 
Concomitant systemic use of clotrimazole and boosted darunavir may increase plasma concentrations of darunavir and/or clotrimazole.
Samtidig anvendelse af salmeterol og darunavir administreret sammen med lavdosis ritonavir anbefales ikke. 
Concomitant use of salmeterol and darunavir co-administered with low dose ritonavir is not recommended.